Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Leukemia, Biphenotypic, Acute 3Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Rituximab 32Cyclophosphamide 28Lenalidomide 19Prednisone 16Doxorubicin 16Vincristine 14Etoposide 11CT-P10 11Gemcitabine 9polatuzumab vedotin 8Oxaliplatin 7ibrutinib 6glofitamab 6fludarabine 6acalabrutinib 6Magnetic Resonance Spectroscopy 6Ifosfamide 6Carboplatin 6tafasitamab 5prednylidene 5pembrolizumab 5obinutuzumab 5deltacortene 5Specimen Handling 5R-CHOP protocol 5Nivolumab 5Biopsy 5venetoclax 4fludarabine phosphate 4selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Large B-Cell, Diffuse × Spinal Puncture × Clear all
NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05359211 2026-03-20

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡